49 results on '"and Canestrari, E."'
Search Results
2. PHLDA1 expression is controlled by an estrogen receptor-NFκB-miR-181 regulatory loop and is essential for formation of ER+ mammospheres
3. Genetic modulation of the Let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab–irinotecan
4. Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer
5. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy
6. Role of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patients
7. High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice
8. Aspects of triterpene chemistry
9. Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and diffuse histotype
10. ASTRI SST-2M: the design evolution from the prototype to the array telescope
11. Characterization of a pathogen reduced human platelet lysate
12. Human platelet lysate as a media supplement for ex vivo expansion of immune cells
13. 171 - Human platelet lysate as a media supplement for ex vivo expansion of immune cells
14. 170 - Characterization of a pathogen reduced human platelet lysate
15. Contributo alla standardizzazione italiana della Scala Vineland II - Survey Form nella popolazione anziana sana e con disturbo di Alzheimer
16. C-MET gene copy number variation (CNV) analysis by quantitative PCR (qPCR) assay in Caucasian patients with gastric cancer (GC)
17. Let-7 micro-RNA levels in KRAS mutated colorectal carcinomas impact on survival of patients treated with salvage cetuximab
18. Correlation of BRAF wild-type status (WT) in primary colorectal tumors with BRAF status in related metastatic sites: Implications for treatment with anti-EGFR antibodies
19. Host geneticd variants in the insulin growth factor binding protein-3 impact on survival of patients with adanced gastric cancer treated with palliative chemotherapy
20. HOST GENETIC VARIANTS IN THE INSULIN GROWTH FACTOR BINDING PROTEIN-3 IMPACT ON SURVIVAL OF PATIENTS WITH ADVANCED GASTRIC CANCER TREATED WITH PALLIATIVE CHEMOTHERAPY
21. VEGF gene polymorphisms in the prediction of benefit from first-line folfiri plus bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients (pts)
22. GENETIC MODULATION OF THE LET-7 MICRO-RNA BINDINGTO KRAS 3’-UNTRANSLATED REGION (3’-UTR) IMPACTS ONSURVIVAL OF METASTATIC COLORECTAL CANCER (MCRC)PATIENTS (PTS) WITH UNRESPONSIVE DISEASE TO SALVAGECETUXIMAB-IRINOTECAN
23. BRAF mutations and EGFR Intron-1 L/L genotype are associated with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients
24. K-RAS status in primary colorectal tumours correlate with K-RAS status in related metastatic sites: implications for treatment with anti-EGFR antibodies in clinical setting
25. Predictive role of a pharmacogenetic profiling in patients with advanced colorectal cancer (ACRC) treated with first-line, 5-fluorouracil/oxaliplatin chemotherapy
26. PHLDA1 expression is controlled by an estrogen receptor-NFκB-miR-181 regulatory loop and is essential for formation of ER+ mammospheres
27. C-MET gene copy number variation (CNV) analysis by quantitative PCR (qPCR) assay in Caucasian patients with gastric cancer (GC).
28. Let-7a microRNA levels in KRAS-mutated colorectal carcinomas determine survival differences in patients treated with anti-EGFR.
29. Molecular Predictors of Efficacy to Anti-EFGR Agents in Colorectal Cancer Patients
30. 6115 VEGF gene polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts)
31. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
32. Association of BRAF mutations and EGFR Intron-1 L/L genotype with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients
33. Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer
34. Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy
35. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy
36. Genetic Activation of the MET Pathway and Prognosis of Patients With High-Risk, Radically Resected Gastric Cancer.
37. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
38. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.
39. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
40. Genetic modulation of the let-7 micro-RNA binding to KRAS 3'-untranslated region impacts on survival of metastatic colorectal cancer patients with unresponsive disease to salvage cetuximab-irinotecan
41. Variations in the Interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer
42. Host genetic variants in the Insulin Growth Factor Binding Protein-3 impact on servival of patients with advanced gastric cancer treated with palliative chemotharapy
43. Genetic modulation of the LET-7 micro-RNA binding to KRAS 3’-untranslated region (3’-UTR) impacts on survival of metastatic colorectal cancer (MCRC) patients (pts) with unresponsive disease to salvage cetuximab-irinotecan
44. Pharmacogenetic profiling for anti-Epidermal Growth Factor Receptor therapy in patients with refractory advanced colorectal cancer
45. Let-7a microRNA levels in KRAS-mutated colorectal carcinomas determine survival differences in patients treated with anti-EGFR
46. VEGF gene polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts)
47. High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice
48. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice
49. Freud,, la 'Bildung' e le 'Gefuehlsmaechte'
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.